The company witnesses strong growth across its India, Africa, and emerging markets businesses, while securing regulatory approval for the first AB-rated gVentolin in the U.S. market
These check-ups will be conducted through ESIC’s extensive network of hospitals, with a focus on early diagnosis, preventive healthcare, and continuous health monitoring
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The company reported net revenue of SEK 13.5 million for the full year 2025
The presentations underscore the company’s deep expertise in dermatology and immunology
Several technologies for hemoglobinopathies are being transferred to commercial partners
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Subscribe To Our Newsletter & Stay Updated
